We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over the past decade, the number of privately funded clinical trials has nearly doubled, while the number of government-sponsored studies have fallen, according to a new report from Johns Hopkins University. Read More
The pharmaceutical industry is becoming more active in sharing clinical trial data in a way that may have seemed inconceivable 20 years ago, drugmakers said, even as it has taken heat for being opaque on disclosures. Read More
The European Medicines Agency is moving to reject substitute proof-of-concept trials in place of GCP noncompliant studies during marketing application reviews. Read More
As the pharmaceutical industry makes its way into the digital age, a new initiative launched at UC San Diego hopes to guide ethics standards on the use of personal health data in clinical trials. Read More
Underscoring the importance of pediatric trial design, cancer experts recently guided drugmakers on whether their research plans for two investigational drugs could be feasibly used to combat some of the most life-threatening and hard-to-treat childhood cancers. Read More
The European Medicines Agency is moving to reject substitute proof-of-concept trials in place of GCP noncompliant studies during marketing application reviews. Read More
The pharmaceutical industry is becoming more active in sharing clinical trial data in a way that may have seemed inconceivable 20 years ago, drugmakers said, even as it has taken heat for being opaque on disclosures. Read More
The FDA is calling for risk management plans for clinical development of microbial vectors for gene therapy, focusing on the potential for vectors to germinate, regerminate or reseed. Read More